Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$1.19 USD
-0.02 (-1.65%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $1.15 -0.04 (-3.36%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Hoth Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 8 | 11 | 14 | 7 | 8 |
Income After Depreciation & Amortization | -8 | -11 | -14 | -7 | -8 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -8 | -11 | -14 | -7 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -11 | -14 | -7 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -11 | -14 | -7 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -11 | -14 | -7 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -11 | -14 | -7 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 1.20 | 0.89 | 0.50 | 0.37 |
Diluted EPS Before Non-Recurring Items | NA | -9.50 | -16.00 | -14.50 | -21.00 |
Diluted Net EPS (GAAP) | -2.30 | -9.50 | -16.00 | -14.50 | -21.00 |
Fiscal Year end for Hoth Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.72 | 2.09 | 1.71 | 2.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.72 | -2.09 | -1.71 | -2.19 |
Non-Operating Income | NA | -0.01 | 0.01 | -0.16 | 0.01 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.70 | -2.09 | -1.87 | -2.18 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.70 | -2.09 | -1.87 | -2.18 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.70 | -2.09 | -1.87 | -2.18 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 3.48 | 3.30 | 2.48 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.60 | -0.57 | -0.88 |
Diluted Net EPS (GAAP) | NA | -0.25 | -0.60 | -0.57 | -0.88 |